ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation

Blood

Volumn 119, Issue 26, 2012, Pages 6268-6277

  Weissmüller, Sabrina ^a   Semmler, Linda Y ^b   Kalinke, Ulrich ^b   Christians, Stefan ^a   Müller Berghaus, Jan ^a   Waibler, Zoe ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY TGN 1412; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION;

EID: 84863522488     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-401083     Document Type: Article

References (42)

1. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47(4):606-608. (Pubitemid 19110914)
2. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology. 1995;105(1):23-29.
3. Sharpe AH. Mechanisms of costimulation. Immunol Rev. 2009;229(1):5-11.
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258. (Pubitemid 26130184)
5. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol. 2001;2(3):203-209. (Pubitemid 33705995)
6. Khayyamian S, Hutloff A, Buchner K, et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A. 2002;99(9):6198-6203. (Pubitemid 34493289)
7. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T-cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22(3):326-332.
8. Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med. 2010;2(55):55ra78.
9. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018-1028. (Pubitemid 44343545)
10. Findlay L, Eastwood D, Stebbings R, et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol Methods. 2010;352(1-2):1-12.
11. Stebbings R, Findlay L, Edwards C, et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol. 2007;179(5):3325-3331.
12. Waibler Z, Sender LY, Merten C, et al. Signaling signatures and functional properties of antihuman CD28 superagonistic antibodies. PLoS One. 2008;3(3):e1708.
13. Parren PW,Warmerdam PA, Boeije LC, Capel PJ, van de Winkel JG, Aarden LA. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. J Immunol. 1992;148(3):695-701.
14. Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ. T-cell activation by anti-T3 antibodies: comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol. 1986;16(5):478-486. (Pubitemid 16103043)
15. Tax WJ, Willems HW, Reekers PP, Capel PJ, Koene RA. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature. 1983;304(5925):445-447. (Pubitemid 13077944)
16. Parleviet KJ, Jonker M, ten Berge RJ, et al. Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation. 1990;50(5):889-892.
17. Rao PE, Olini G, Kille J, et al. OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees. Transplantation. 1991;52(4):691-697.
18. Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200(1):16-26. (Pubitemid 30170076)
19. Waibler Z, Sender LY, Kamp C, et al. Toward experimental assessment of receptor occupancy: TGN1412 revisited. J Allergy Clin Immunol. 2008;122(5):890-892.
20. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21-50. (Pubitemid 46697901)
21. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
22. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4(2):89-99. (Pubitemid 38209203)
23. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71(7):1065-1068. (Pubitemid 23016541)
24. Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973-975. (Pubitemid 44343539)
25. Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161(3):512-526.
26. Römer PS, Berr S, Avota E, et al. Preculture of PBMC at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 2011;118(26):6772-6782
27. Findlay L, Sharp G, Fox B, et al. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine. 2011;55(1):141-151.
28. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-3561. (Pubitemid 28225719)
29. Pober JS. Immunobiology of human vascular endothelium. Immunol Res. 19(2-3):225-232, 1999. (Pubitemid 29401379)
30. Rose ML. Endothelial cells as antigen-presenting cells: role in human transplant rejection. Cell Mol Life Sci. 1998;54(9):965-978. (Pubitemid 28461685)
31. Savage CO, Brooks CJ, Harcourt GC, et al. Human vascular endothelial cells process and present autoantigen to human T cell lines. Int Immunol. 1995;7(3):471-479.
32. Vora M, Yssel H, de Vries JE, Karasek MA. Antigen presentation by human dermal microvascular endothelial cells. Immunoregulatory effect of IFN-gamma and IL-10. J Immunol. 1994;152(12):5734-5741. (Pubitemid 24174152)
33. Hughes CC, Savage CO, Pober JS. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med. 1990;171(5):1453-1467. (Pubitemid 20167543)
34. Kunitomi A, Hori T, Imura A, Uchiyama T. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J Leukoc Biol. 2000;68(1):111-118.
35. Yao S, Zhu Y, Zhu G, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity. 2011;34(5):729-740.
36. Mesturini R, Nicola S, Chiocchetti A, et al. ICOS cooperates with CD28, IL-2, and IFN-gamma and modulates activation of human naive CD4+ T cells. Eur J Immunol. 2006;36(10):2601-2612. (Pubitemid 44608444)
37. Dong C, Juedes AE, Temann UA, et al. ICOS costimulatory receptor is essential for T-cell activation and function. Nature. 2001;409(6816):97-101. (Pubitemid 32098632)
38. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature. 2001;409(6816):102-105. (Pubitemid 32098633)
39. Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature. 2001;409(6816):105-109. (Pubitemid 32098634)
40. Takahashi N, Matsumoto K, Saito H, et al. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOSdeficient patients. J Immunol. 2009;182(9):5515-5527.
41. Chen H, Liakou CI, Kamat A, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009;106(8):2729-2734.
42. Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105(39):14987-14992.